^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PGR negative

    i
    Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    Entrez ID:
    5241
    Related biomarkers:
    Expression
    Mutation
    Others
    11ms
    Efficacy and Safety of Ivonescimab Injection Combined with Nab-Paclitaxel Plus Lobaplatin as Neoadjuvant Therapy for Triple-Negative Breast Cancer in Stages II-III: A Prospective, Multicenter, Single-Arm Study (ChiCTR2400094426)
    P4, N=91, Recruiting, The First Affiliated Hospital of Army Medical University, PLA; The First Affiliated Hospital of Army Medical University, PLA
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 amplification • HER-2 negative • ER negative • PGR negative
    |
    albumin-bound paclitaxel • lobaplatin (D19466) • Yidafan (ivonescimab)
    11ms
    Parental loss at age 0-21 and daughters' breast cancer and tumor characteristics. (PubMed, JNCI Cancer Spectr)
    Death of one or both parents during childhood was strongly associated with BrCa and aggressive disease. Parental death during childhood could be added to medical histories to indicate counseling regarding prevention and early detection of BrCa.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER negative • PGR negative
    11ms
    FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, University of Wisconsin, Madison | Trial completion date: Jan 2025 --> Dec 2025
    Trial completion date
    |
    PGR (Progesterone receptor)
    |
    PGR negative
    11ms
    Adenylate cyclase 9 expression level is associated with hormone receptor-positive breast cancer and predicts patient prognosis. (PubMed, Nagoya J Med Sci)
    The C/N ratio of ADCY9 was found as an independent prognostic factor for disease-free survival. Thus, ADCY9 expression is high in hormone receptor-positive breast cancer, and its low expression indicates a poor prognosis in patients with breast cancer.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • TGFB1 (Transforming Growth Factor Beta 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    ER positive • HR positive • ER negative • PGR positive • PGR negative
    11ms
    CAR T Cells in Mesothelin-Expressing Breast Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Pennsylvania | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MSLN (Mesothelin)
    |
    ER positive • HER-2 negative • ER negative • MSLN expression • PGR positive • PGR negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    11ms
    A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Recruiting, University of Southern California | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CTAG1B (Cancer/testis antigen 1B)
    |
    HER-2 negative • PGR negative
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR
    11ms
    A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=169, Completed, Cyteir Therapeutics, Inc. | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Dec 2024
    Trial completion • Trial completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative • HER-2 negative + AR positive + ER positive • HER-2 negative + PGR positive
    |
    gemcitabine • Rituxan (rituximab) • capecitabine • bendamustine • CYT-0851
    12ms
    Association of the SNPs in CCL2 and CXCL12 genes with the susceptibility to breast cancer: a case-control study in China. (PubMed, Front Oncol)
    CCL2 and CXCL12 SNPs are associated with breast cancer susceptibility in overweight and postmenopausal women, and the effect varies according to subtypes. The interaction of SNPs within CXCL12 gene and the association with breast cancer survival further suggest potential targets for improved risk assessment and treatment strategies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CCL2 (Chemokine (C-C motif) ligand 2)
    |
    HER-2 positive • ER negative • PGR negative
    12ms
    Anti‑proliferative effects of Drynaria fortunei in a model for triple negative breast cancer. (PubMed, Oncol Lett)
    It is typically responsive to anthracycline/taxol-based conventional chemotherapy...These data identify potential mechanistic leads for anti-proliferative and pro-apoptotic effects of DF in the present TNBC model. The present experiments validated a mechanism-driven experimental approach to identify efficacious nutritional herbs and/or their bioactive constituents as treatment alternatives for TNBC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CDK4 (Cyclin-dependent kinase 4) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • CASP7 (Caspase 7) • E2F1 (E2F transcription factor 1)
    |
    HER-2 negative • ER negative • PARP1 expression • PGR negative • CDK2 expression
    |
    paclitaxel
    12ms
    Association between long-term ambient air pollution exposure and the incidence of breast cancer: A meta-analysis based on updated evidence. (PubMed, Ecotoxicol Environ Saf)
    This study is the first to document a significant association between long-term exposure to ambient PM2.5 and breast cancer incidence through meta-analysis. Air pollution has a pronounced impact on postmenopausal breast cancer, and the strength of the association between specific air pollutants and breast cancer incidence varies across regions. These findings suggest that long-term exposure to NO2 and PM2.5 may increase the incidence of breast cancer.
    Retrospective data • Review • Journal
    |
    PGR (Progesterone receptor)
    |
    ER positive + PGR positive • PGR positive • PGR negative
    12ms
    OptiTROP-Breast01: SKB264 Injection Vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=254, Active, not recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Trial completion date: Dec 2024 --> Mar 2025
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 expression • PGR negative • HER-2 negative + HR positive + BRCA mutation
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)
    12ms
    FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, University of Wisconsin, Madison | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PGR (Progesterone receptor)
    |
    PGR negative